Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TJX COMPANIES INC /DE/TJX · Entity 2870 | Director | June 09, 2026 | June 11, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, CO & FO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TJX COMPANIES INC /DE/
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,126.12 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 636.87 · Balance 3,126.12 F1: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,152.62 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 26.5 · Balance 3,152.62 F2: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,126.12 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 636.87 · Balance 3,126.12 F3: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,152.62 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 26.5 · Balance 3,152.62 F4: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an annual award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares will be delivered following the Director's departure from the Board, under and subject to the terms of the Plan.
F2: Constitutes an award of deferred shares under the Stock Incentive Plan having a grant date fair value equal to the aggregate dividends on any previously granted annual award of deferred shares under the Plan for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the annual award are delivered, under and subject to the terms of the Plan.
F3: Constitutes an additional award of deferred shares under the Stock Incentive Plan having a grant date fair value of $105,000. Shares vest on the date immediately preceding the date of the Company's annual meeting of shareholders next succeeding the award grant date, provided that the recipient is still a Director on that date or, to the extent provided by the terms of the award document, in connection with an earlier Change of Control. Vested shares will be delivered following vesting or following the Director's departure from the Board, in accordance with the Director's advance irrevocable election, if any, under and subject to the terms of the Plan.
F4: Constitutes an award of deferred shares under the Stock Incentive Plan having a value equal to the aggregate dividends on any previously granted additional award of deferred shares under the Plan, which have not yet been delivered to the Director, and for which there has been a record date since June 10, 2025. Deferred shares will be delivered at the same time the shares subject to the applicable additional award are delivered, under and subject to the terms of the Plan.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,042 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 1,744 · Balance 47,042 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $296.30 | $71,112.00 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,995 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $296.30 (range $296.14 to $296.45). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 784 | $295.43 | $231,617.12 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,235 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $295.43 (range $295.09 to $295.97). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 360 | $294.52 | $106,027.20 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,019 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $294.52 (range $293.98 to $294.81). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 62 | $296.77 | $18,399.74 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 14 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 292 | $295.89 | $86,399.88 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 13 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,441 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 715 | $294.52 | $210,581.80 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 12 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,733 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,153 | $293.35 | $338,232.55 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 11 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,448 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 420 | $292.41 | $122,812.20 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 10 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,061 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 24 | $288.31 | $6,919.44 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 9 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,021 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 102 | $294.94 | $30,083.88 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 8 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,045 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 27 | $293.61 | $7,927.47 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 7 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,147 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 185 | $292.68 | $54,145.80 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,174 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 541 | $291.47 | $157,685.27 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,359 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30 | $289.44 | $8,683.20 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,900 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 327 | $288.91 | $94,473.57 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,930 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 515 | $287.83 | $148,232.45 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,257 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 361 | $286.64 | $103,477.04 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,772 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013774 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,133 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011707 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,441 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,992 | $298.26 | $1,488,913.92 |
DisclosureSEC source: 0001209191-23-009243 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,191 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,707 | $294.33 | $796,751.31 |
DisclosureSEC source: 0001209191-23-009243 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,183 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,890 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,450 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007012 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,188 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3 | $264.37 | $793.11 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 7 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,730 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 32 | $262.06 | $8,385.92 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,733 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $262.06 (range $261.89 to $262.23). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 48 | $261.15 | $12,535.20 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,765 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $261.15 (range $260.79 to $261.63). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $259.45 | $20,756.00 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,813 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $259.45 (range $258.98 to $259.90). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 60 | $258.21 | $15,492.60 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,893 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $258.21 (range $257.98 to $258.61). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $257.18 | $25,718.00 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,953 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $257.18 (range $256.68 to $257.47). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20 | $254.87 | $5,097.40 |
DisclosureSEC source: 0000899243-22-016635 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,053 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 547 | $276.17 | $151,064.99 |
DisclosureSEC source: 0000899243-22-016318 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,073 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 223 | $266.68 | $59,469.64 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,620 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $266.68 (range $266.55 to $266.83). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 536 | $265.95 | $142,549.20 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,843 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $265.95 (range $265.55 to $266.47). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,142 | $265.06 | $302,698.52 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $265.06 (range $264.53 to $265.48). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 381 | $263.67 | $100,458.27 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,521 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $263.67 (range $263.45 to $264.42). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $261.42 | $78,426.00 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,902 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $261.42 (range $261.04 to $261.80). Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 61 | $251.05 | $15,314.05 |
DisclosureSEC source: 0000899243-22-011703 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,202 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,110 | $250.13 | $777,904.30 |
DisclosureSEC source: 0000899243-22-011703 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,263 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $250.13 (range $250.00 to $250.61). F3 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,189 | $227.86 | $498,785.54 |
DisclosureSEC source: 0000899243-22-008128 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,373 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,439 | $232.51 | $799,601.89 |
DisclosureSEC source: 0000899243-22-007217 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,562 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,434 | $237.74 | $578,659.16 |
DisclosureSEC source: 0001209191-22-009252 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,001 Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,944 | $250.07 | $736,206.08 |
DisclosureSEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,435 F4 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $250.07 (range $250.00 to $250.09). F6 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,379 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 11,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,117 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,489 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 04/10/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. Read SEC document |
| April 30, 2021 Filed May 6, 2021 01:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 547 | $217.21 | $118,813.87 |
DisclosureSEC source: 0001209191-21-030524 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,679 Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 547 | $217.57 | $119,010.79 |
DisclosureSEC source: 0001209191-21-014759 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,226 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,365 | $214.16 | $506,488.40 |
DisclosureSEC source: 0001209191-21-010133 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,773 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008168 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,138 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.